RU2015134581A - Доноры нитроксила с улучшенным терапевтическим индексом - Google Patents

Доноры нитроксила с улучшенным терапевтическим индексом Download PDF

Info

Publication number
RU2015134581A
RU2015134581A RU2015134581A RU2015134581A RU2015134581A RU 2015134581 A RU2015134581 A RU 2015134581A RU 2015134581 A RU2015134581 A RU 2015134581A RU 2015134581 A RU2015134581 A RU 2015134581A RU 2015134581 A RU2015134581 A RU 2015134581A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
compound
paragraphs
composition according
formula
Prior art date
Application number
RU2015134581A
Other languages
English (en)
Other versions
RU2676277C2 (ru
Inventor
Винсент Джейкоб КАЛИШ
Фредерик Артур Брукфилд
Стефен Мартин КОРТНИ
Лиза Мари ФРОСТ
Джон П. ТОСКАНО
Original Assignee
Кардиоксил Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кардиоксил Фармасьютикалз, Инк. filed Critical Кардиоксил Фармасьютикалз, Инк.
Publication of RU2015134581A publication Critical patent/RU2015134581A/ru
Application granted granted Critical
Publication of RU2676277C2 publication Critical patent/RU2676277C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Claims (23)

1. Соединение формулы (1):
Figure 00000001
2. Соединение формулы (2):
Figure 00000002
3. Фармацевтическая композиция, содержащая соединение по п. 1 или 2 и по меньшей мере одно фармацевтически приемлемое вспомогательное вещество.
4. Фармацевтическая композиция по п. 3, где фармацевтическая композиция является подходящей для внутривенного введения.
5. Фармацевтическая композиция по п. 3 или 4, где фармацевтическая композиция имеет значение рН от приблизительно 4 до приблизительно 6.
6. Фармацевтическая композиция по п. 3 или 4, где фармацевтическая композиция имеет значение рН от приблизительно 4 до приблизительно 5.
7. Фармацевтическая композиция по п. 3 или 4, где фармацевтическая композиция имеет значение рН приблизительно 4.
8. Способ лечения сердечно-сосудистого заболевания, включающий введение эффективного количества соединения по п. 1 или 2 или фармацевтической композиции по любому из пп. 3-7 пациенту, имеющему потребность в лечении.
9. Способ по п. 8, в котором сердечно-сосудистое заболевание представляет собой сердечную недостаточность.
10. Способ по п. 8, в котором сердечно-сосудистое заболевание представляет собой острую декомпенсированную сердечную недостаточность.
11. Способ по любому из пп. 8-10, в котором соединение или фармацевтическую композицию вводят внутривенно.
12. Способ по любому из пп. 8-10, в котором соединение или фармацевтическую композицию вводят в дозе от приблизительно 20 мкг/кг/мин соединения формулы (1) или (2) до приблизительно 40 мкг/кг/мин соединения формулы (1) или (2).
13. Способ по любому из пп. 8-10, в котором соединение или фармацевтическую композицию вводят перорально.
14. Набор, содержащий соединение по п. 1 или 2, в сухом виде или фармацевтическую композицию по любому из пп. 3-7 в сухом виде; и фармацевтически приемлемый жидкий разбавитель.
15. Применение соединения по п. 1 или 2 или применение фармацевтической композиции по любому из пп. 3-7 для получения лекарственного средства, используемого для лечения сердечно-сосудистого заболевания.
16. Применение соединения по п. 1 или 2 или применение фармацевтической композиции по любому из пп. 3-7 для получения лекарственного средства, используемого для лечения сердечной недостаточности.
17. Применение соединения по п. 1 или 2 или применение фармацевтической композиции по любому из пп. 3-7 для получения лекарственного средства, используемого для лечения острой декомпенсированной сердечной недостаточности.
18. Соединение по п. 1 или 2 или фармацевтическая композиция по любому из пп. 3-7, для использования в лечении сердечно-сосудистого заболевания.
19. Соединение по п. 1 или 2 или фармацевтическая композиция по любому из пп. 3-7 для использования в лечении сердечной недостаточности.
20. Соединение по п. 1 или 2 или фармацевтическая композиция по любому из пп. 3-7 для использования в лечении острой декомпенсированной сердечной недостаточности.
21. Способ по п. 11, в котором соединение или фармацевтическую композицию вводят в дозе от приблизительно 20 мкг/кг/мин соединения формулы (1) или (2) до приблизительно 40 мкг/кг/мин соединения формулы (1) или (2).
RU2015134581A 2013-01-18 2014-01-17 Доноры нитроксила с улучшенным терапевтическим индексом RU2676277C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US61/754,237 2013-01-18
US201361782781P 2013-03-14 2013-03-14
US61/782,781 2013-03-14
PCT/US2014/012085 WO2014113696A1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018143994A Division RU2018143994A (ru) 2013-01-18 2014-01-17 Доноры нитроксила с улучшенным терапевтическим индексом

Publications (2)

Publication Number Publication Date
RU2015134581A true RU2015134581A (ru) 2017-02-27
RU2676277C2 RU2676277C2 (ru) 2018-12-27

Family

ID=50064795

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2015134581A RU2676277C2 (ru) 2013-01-18 2014-01-17 Доноры нитроксила с улучшенным терапевтическим индексом
RU2015134583A RU2684916C2 (ru) 2013-01-18 2014-01-17 Фармацевтические композиции, содержащие доноры нитроксила
RU2018143994A RU2018143994A (ru) 2013-01-18 2014-01-17 Доноры нитроксила с улучшенным терапевтическим индексом

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2015134583A RU2684916C2 (ru) 2013-01-18 2014-01-17 Фармацевтические композиции, содержащие доноры нитроксила
RU2018143994A RU2018143994A (ru) 2013-01-18 2014-01-17 Доноры нитроксила с улучшенным терапевтическим индексом

Country Status (28)

Country Link
US (13) US10245249B2 (ru)
EP (5) EP3284463B1 (ru)
JP (5) JP6449171B2 (ru)
KR (2) KR102177899B1 (ru)
CN (4) CN108610312A (ru)
AU (5) AU2014207408C1 (ru)
BR (2) BR112015017241B1 (ru)
CA (2) CA2898445C (ru)
CY (3) CY1120535T1 (ru)
DK (3) DK3284463T3 (ru)
ES (4) ES2882279T3 (ru)
HK (3) HK1216857A1 (ru)
HR (3) HRP20180121T1 (ru)
HU (3) HUE046722T2 (ru)
IL (4) IL239906B (ru)
LT (3) LT2945620T (ru)
MX (2) MX2015009276A (ru)
NZ (4) NZ709985A (ru)
PL (3) PL3284463T3 (ru)
PT (3) PT3284463T (ru)
RS (3) RS58174B1 (ru)
RU (3) RU2676277C2 (ru)
SG (6) SG11201505567RA (ru)
SI (3) SI2945620T1 (ru)
TR (1) TR201802211T4 (ru)
TW (3) TWI712409B (ru)
WO (2) WO2014113696A1 (ru)
ZA (2) ZA201505090B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2586435T1 (sl) 2006-03-17 2016-12-30 The Johns Hopkins University Derivati N-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
MX363306B (es) 2011-10-17 2019-03-20 Univ Johns Hopkins Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).
EP3284463B1 (en) 2013-01-18 2019-07-24 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
EP3348548A4 (en) 2015-09-07 2019-04-03 Zhejiang Huahai Pharmaceutical Co., Ltd DRUG MOLECULE RELEASING NITRIC OXIDE
US10730828B2 (en) 2015-10-19 2020-08-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
EP3365328A1 (en) 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
ES2878060T3 (es) 2016-07-28 2021-11-18 Univ Johns Hopkins Acidos hidroxámicos O-sustituidos
WO2018128999A1 (en) * 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
AU2018254743B2 (en) * 2017-04-18 2024-04-11 Genfit Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
ATE66143T1 (de) 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
WO1995019952A1 (de) * 1994-01-19 1995-07-27 Byk Nederland Bv Nitroxy-gruppen enthaltende benzylaminderivate und ihre verwendung zur behandlung von cardiovasculären erkrankungen sowie erhöhtem augeninnendruck
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
BR9812982A (pt) 1997-10-24 2000-08-08 Shionogi & Co Agente anti-reumático
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
US6295153B1 (en) 1998-06-04 2001-09-25 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (ru) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетки с энтеросолюбильным покрытием и способ их получения
DE69924735T2 (de) 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
ES2267853T3 (es) 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
CA2554771A1 (en) 2004-01-30 2005-08-18 Johns Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
SI2586435T1 (sl) 2006-03-17 2016-12-30 The Johns Hopkins University Derivati N-hidroksilsulfonamida kot novi fiziološko uporabni donorji nitroksila
WO2007120839A2 (en) 2006-04-13 2007-10-25 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
JP2011502105A (ja) 2007-09-26 2011-01-20 ジョンズ ホプキンス ユニバーシティ 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
WO2009137717A1 (en) 2008-05-07 2009-11-12 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
CA2782248A1 (en) 2009-12-07 2011-06-16 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
MX363306B (es) 2011-10-17 2019-03-20 Univ Johns Hopkins Derivados del acido de meldrum, acido barbiturico y pirazolona sustituidos con hidroxilamina como donadores de nitroxilo (hno).
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
EP3284463B1 (en) 2013-01-18 2019-07-24 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors with improved therapeutic index
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
JP2016505044A (ja) 2016-02-18
NZ709986A (en) 2020-01-31
ZA201505090B (en) 2016-10-26
US20190133990A1 (en) 2019-05-09
BR112015017241A8 (pt) 2019-10-29
LT2945620T (lt) 2018-02-12
US10792273B2 (en) 2020-10-06
CA2898445A1 (en) 2014-07-24
IL259233B (en) 2019-10-31
RU2676277C2 (ru) 2018-12-27
WO2014113700A9 (en) 2014-10-09
US9156804B2 (en) 2015-10-13
LT3284463T (lt) 2019-11-11
TW201446242A (zh) 2014-12-16
BR112015017241A2 (pt) 2017-07-11
AU2014207408B2 (en) 2018-03-01
CN110179777A (zh) 2019-08-30
US20210015784A1 (en) 2021-01-21
JP2019172682A (ja) 2019-10-10
US20180235927A1 (en) 2018-08-23
RU2015134583A (ru) 2017-02-22
TWI712409B (zh) 2020-12-11
NZ748771A (en) 2019-12-20
HRP20191919T8 (hr) 2021-10-01
MX363843B (es) 2019-04-05
DK3284463T3 (da) 2019-10-28
AU2018241168A1 (en) 2018-11-01
BR112015017251B1 (pt) 2021-10-26
IL239906B (en) 2018-05-31
US20200163929A1 (en) 2020-05-28
AU2018203240B2 (en) 2019-12-12
US10213408B2 (en) 2019-02-26
HK1251170B (zh) 2020-04-09
CY1122177T1 (el) 2020-11-25
HUE036589T2 (hu) 2018-07-30
HK1216858A1 (zh) 2016-12-09
HK1216857A1 (zh) 2016-12-09
IL239952B (en) 2018-05-31
SG10201802855TA (en) 2018-05-30
EP3427728B1 (en) 2021-07-07
US20140206769A1 (en) 2014-07-24
PT3284463T (pt) 2019-10-30
US8987326B2 (en) 2015-03-24
KR102277165B1 (ko) 2021-07-14
MX2015009276A (es) 2015-10-30
US11273143B2 (en) 2022-03-15
SI2945621T1 (sl) 2019-01-31
LT2945621T (lt) 2019-01-10
US20220193026A1 (en) 2022-06-23
AU2014207408A8 (en) 2015-08-27
AU2018203240A1 (en) 2018-05-31
ES2705240T3 (es) 2019-03-22
US9586896B2 (en) 2017-03-07
AU2014207408A1 (en) 2015-08-13
CA2898443A1 (en) 2014-07-24
US11786501B2 (en) 2023-10-17
US10517847B2 (en) 2019-12-31
CN105073105B (zh) 2018-02-27
KR20150108879A (ko) 2015-09-30
TW201442702A (zh) 2014-11-16
CN105142627B (zh) 2019-06-21
IL239906A0 (en) 2015-08-31
BR112015017251A8 (pt) 2019-10-29
EP3567031A1 (en) 2019-11-13
CN110179777B (zh) 2022-07-15
CN108610312A (zh) 2018-10-02
SI2945620T1 (en) 2018-01-31
EP3284463A1 (en) 2018-02-21
PT2945621T (pt) 2019-01-21
SG10201802862WA (en) 2018-05-30
RS58174B1 (sr) 2019-03-29
JP2019089764A (ja) 2019-06-13
JP6801045B2 (ja) 2020-12-16
EP3427728A1 (en) 2019-01-16
NZ748769A (en) 2020-05-29
TWI686193B (zh) 2020-03-01
PL2945620T3 (pl) 2018-03-30
DK2945620T3 (en) 2018-02-05
NZ709985A (en) 2020-05-29
IL239952A0 (en) 2015-08-31
SG10201913286PA (en) 2020-02-27
BR112015017241B1 (pt) 2021-10-26
AU2014207408C1 (en) 2018-09-06
CY1121480T1 (el) 2020-05-29
US20150175566A1 (en) 2015-06-25
RU2018143994A (ru) 2019-01-16
HRP20182144T1 (hr) 2019-03-08
JP2016510326A (ja) 2016-04-07
US20240066002A1 (en) 2024-02-29
JP6449171B2 (ja) 2019-01-09
IL258882A (en) 2018-06-28
EP2945620A1 (en) 2015-11-25
US11304924B2 (en) 2022-04-19
AU2017200147B2 (en) 2018-07-05
EP2945620B1 (en) 2017-11-22
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
US9968584B2 (en) 2018-05-15
PT2945620T (pt) 2018-02-21
CA2898443C (en) 2022-05-31
AU2014207404B2 (en) 2017-10-19
HUE041861T2 (hu) 2019-06-28
JP2017125015A (ja) 2017-07-20
KR20150107853A (ko) 2015-09-23
EP3284463B1 (en) 2019-07-24
ES2659969T3 (es) 2018-03-20
IL259233A (en) 2018-07-31
DK2945621T3 (en) 2019-02-11
AU2014207404A1 (en) 2015-08-13
RS59434B1 (sr) 2019-11-29
CA2898445C (en) 2022-05-03
RU2684916C2 (ru) 2019-04-16
US10548872B2 (en) 2020-02-04
ZA201604798B (en) 2018-01-31
PL2945621T3 (pl) 2019-05-31
CN105142627A (zh) 2015-12-09
TR201802211T4 (tr) 2018-03-21
PL3284463T3 (pl) 2019-12-31
ES2882279T3 (es) 2021-12-01
MX2015009269A (es) 2015-10-30
JP6311038B2 (ja) 2018-04-11
SI3284463T1 (sl) 2019-12-31
KR102177899B1 (ko) 2020-11-12
US10245249B2 (en) 2019-04-02
AU2018241168B2 (en) 2020-04-02
US20190224159A1 (en) 2019-07-25
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
HRP20191919T1 (hr) 2020-01-10
BR112015017251A2 (pt) 2017-07-11
WO2014113696A1 (en) 2014-07-24
JP6656345B2 (ja) 2020-03-04
SG11201505567RA (en) 2015-09-29
TW201934120A (zh) 2019-09-01
WO2014113700A1 (en) 2014-07-24
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
JP6533159B2 (ja) 2019-06-19
HRP20180121T1 (hr) 2018-02-23
HUE046722T2 (hu) 2020-03-30
TWI619491B (zh) 2018-04-01
SG10201913441RA (en) 2020-03-30
ES2751922T3 (es) 2020-04-02
CN105073105A (zh) 2015-11-18
US20170151210A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
RU2013121788A (ru) Ингибиторы репликации вич
RU2010141579A (ru) Режим дозировки селективного агониста рецептора s1p1
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2016510326A5 (ru)
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2018513188A5 (ru)
JP2017501154A5 (ru)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2013541583A5 (ru)
JP2018531605A5 (ru)
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
JP2019535830A5 (ru)
RU2020120876A (ru) Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
RU2014150946A (ru) Способ снижения веса
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
Suzuki et al. Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
EA201590825A1 (ru) Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности
CN104547150A (zh) 消炎止痛外用药做为肿瘤、痈疮治疗口服剂的应用
RU2018119120A (ru) D-пролиновые производные в качестве агента, уменьшающего количество sap
RU2015133365A (ru) Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
RU2015131803A (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения